Chinese

Lung CancerClinical Solutions

Home>Clinical Solutions>Cancer>Lung Cancer

Early Screening Companion diagnosis Toxicity Evaluation Drug Resistance Technology platform Service process
Early Screening

Fei Jiean: Benign and malignant lung nodules screening,The differential diagnosis of small pulmonary nodules (lung cancer or non lung cancer) is performed by using biomarkers and clinical features, combined with AI.   

1493706400479151PwxC.jpgAt present, lung cancer has the highest incidence and mortality rate in China, and the early diagnosis rate is low, most of them (~85%) have been diagnosed as III-IV stage;                                              

1493706400479151PwxC.jpglow dose spiral CT (LDCT) is used to screen high risk population recommended by Guideline; However, the low specificity of LDCT leads to a false positive rate of up to 96%, leading to over detection and over treatment, and to increase the patient's psychological stress and reduce life quality.

1493706400479151PwxC.jpgThe introduction of the test will make up for the low specificity of LDCT and reduce the false positive, especially for patients with nodular 5-10mm increase the credibility of the diagnosis.

Companion diagnosis

Aikeyin:   Targeted drug companion diagnosis for tumor tissue samples based on NGS technology platform. The whole exon region and partial intron of nearly 600 tumor related genes can be fully covered and rapidly detected by the technology of target segment capture, given targeted medication guidance and the chemotherapy sensitive tips.                                          

1493706400479151PwxC.jpgAikeyin I:

Comprehensive, disposable detection of ~600 tumor related genes, covering almost all tumor related genes and all targeted drug sites.

Accurate: repeat detection of more than 1000 times per locus, error rate less than 1%.   

1493706400479151PwxC.jpgAikeyin II: a one-time detection of nearly 70 of the currently known and highly related cancer genes; each locus is repeated more than 1000 times, error rate less than 1%.               


Si Yueyin:  Non-invasive NGS testing for cancer patients with blood samples of ctDNA.  Accurate detection of DNA gene in exon region and partial intron region of nearly 600 tumor related genes by target segment capture.  It can be used to guide the targeted therapy of ctDNA in patients with inoperable advanced tumor and the detection of genes related to radiotherapy and chemotherapy. 

1493706400479151PwxC.jpgSi Yueyin I: 

Comprehensive, disposable detection of nearly 600 tumor related genes, covering almost all tumor related genes and all targeted drug sites.

Accurate: repeat detection of more than 10000 times per locus, error rate less than 1%.

Noninvasive: capture tumor DNA directly from the peripheral blood, to avoid traumatic tissue biopsy.                                   

1493706400479151PwxC.jpgSi Yueyin II: a one-time detection of  ~ 70 of the currently known and highly related cancer genes;

Toxicity Evaluation

Taking Platinum-based drug, a chemotherapy drug commonly used in lung cancer, as an example: 

1493706400479151PwxC.jpgBecause of the side effects and drug resistance of platinum-based drugs, the treatment efficiency and the median survival rate are not satisfactory. For this reason, the key to make patients benefit is to find out the drug sensitivity index and molecular markers for prognosis of patients. 

1493706400479151PwxC.jpgPlatinum-based drug acts on guanine in DNA molecules in tumor cells,  forming a covalent platinum-DNA adduct. It can cause the DNA molecular chain and the cross-linking between the chains to interfere with the synthesis of DNA in tumor cells and produce cytotoxic effect. A variety of nucleotide excision repair pathway can remove the platinum-DNA adduct, repair DNA chain or chain-crossing links, resulting in resistance.

1493706400479151PwxC.jpgERCC1 is the rate limiting gene in nucleotide excision repair pathway. Research shows that in the lung cancer cell line A549,  patients with high ERCC1 expression are resistant to platinum; while ERCC1 negative tumors not only benefit from platinum chemotherapy, but also, as a prognostic factor, obtain a longer overall survival rate.

1493706400479151PwxC.jpgERCC1 can be used as a prognostic factor for patients receiving adjuvant chemotherapy with platinum-based drug after NSCLC operations.Patients with high ERCC1 expression have a relatively poor prognosis, and they are not recommended to receive platinum-based chemotherapy.In contrast, patients with low ERCC1 expression have a better prognosis, and they are recommended to receive platinum-based chemotherapy.

1493706400479151PwxC.jpgBRCA1 is a basic component of the DNA damage repair pathway and microtubule damage response pathway.   It has been reported that patientts with low BRCA1 expression level are highly sensitive to platinum-based drug, while  patients with high BRCA1 expression are more sensitive to microtubule drug.

Drug Resistance

Si Yueyin:  Non-invasive NGS testing for cancer patients with blood samples of ctDNA.  Accurate detection of DNA gene in exon region and partial intron region of nearly 600 tumor related genes by target segment capture. A comprehensive and accurate grasp of new mutations in the tumor, in particular, it can be used to detect the presence of drug-resistant sites in patients during treatment, so as to reverse the disease in a reversible phase by changing the treatment.                                      

1493706400479151PwxC.jpgEGFR TKI and ALK TKI are common lung cancer targeted drugs, the drug resistances often coexist with multiple mechanisms. Apart from 60% of patients with EGFR may be related to T790M mutation, the other are related to non-hot spot mutation sites in EGFR or unusual fusion modes.  In addition, HER-2 insertion, amplification, MET amplification, BRAF, EMT, PIK3CA mutation, KIT amplification, ALK mutation, amplification, deletion of EGFR-19, or the production of new driving genes, all lead to resistance.                                       

1493706400479151PwxC.jpgTherefore, it is recommended not to be limited to a single gene or a few known single or multiple SNPs for resistance monitoring. 

More extensive testing can identify whether patients in treatment have a site of resistance or not, and meanwhile providing new targeted drugs with concomitant detection in order to reverse the disease in a reversible phase by changing the treatment.  

Technology platform
Illumina HiSeqSNP polymorphism detectionDigital pathologyMolecule pathology
PCRGene liquid biopsyWhole Exon sequencingGene bank data analysis


Service process

流程.jpg

TOP